EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 in animal models

Nicholas C Hazell, Rachel A Reyna, Awadalkareem Adam, Srinivasa Reddy Bonam, Jiani Bei, Naveen Kumar, Tina N Nguyen, Jessica A Plante, Tong Wu, David H Walker, Tian Wang, Kenneth S Plante und 1 weitere

Journal of Virology · 2026

DOI: 10.1128/jvi.01897-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2026. Verfasst von Nicholas C Hazell und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, SARS-CoV-2, Antibodies, Viral, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibodies represent potent biological countermeasures against a wide range of human diseases; however, their clinical application and widespread use are limited by the high cost and complexity of antibody production and manufacturing. The mRNA-lipid nanoparticle (mRNA-LNP) platform offers a versatile strategy for vaccine development and protein-replacement therapies. Since the COVID-19 pandemic, a number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies have been identified, with several granted emergency use authorization for patients. Here, we report the design and generation of mRNA-LNPs encoding two SARS-CoV-2-neutralizing antibodies, 76E1 and LY1404, which, respectively, target the spike protein’s fusion peptide (FP) and receptor-binding domain (RBD). We demonstrated that a single intramuscular administration of these mRNA-LNPs in mice resulted in robust antibody production that sustained in circulation for 7–14 days. Furthermore, we evaluated protective effects of these mRNA-delivered antibodies in animal models and showed that a single IM dose of mRNA-LNPs encoding LY1404 or 76E1 conferred significant protection against multiple SARS-CoV-2 variants, including Omicron BQ.1 and Delta, in mice and hamsters. Collectively, these findings highlight the potential of mRNA-based antibody delivery for rapid prevention or treatment of pathogenic infections. IMPORTANCE Neutralizing antibodies represent potent biological countermeasures against viral infections. However, the high cost of antibody production restricts its clinical accessibility and large-scale application. The mRNA-lipid nanoparticle (mRNA-LNP) offers a versatile platform for developing vaccines and protein-replacement therapies. In this study, we designed and generated mRNA-LNPs encoding two SARS-CoV-2-neutralizing antibodies, 76E1 and LY1404, which target the viral spike protein’s fusion peptide (FP) and receptor-binding domain (RBD), respectively. A single intramuscular administration of mRNA-LNPs encoding LY1404 or 76E1 resulted in rapid antibody production in circulation and conferred protection against multiple strains of SARS-CoV-2 infection in animal models. Our findings highlight the potential of mRNA-based antibody delivery for rapid prevention or treatment of pathogenic infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingSARS-CoV-2Antibodies, ViralCOVID-19RNA, MessengerAnimalsMiceDisease Models, AnimalFemaleSpike Glycoprotein, CoronavirusHumansNanoparticlesMice, Inbred BALB CCOVID-19 VaccinesAntibodies, MonoclonalLiposomes

Stichwörter der Autor:innen

SARS-CoV-2animal modelsantibodiesmRNA

Substanzen

Antibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, CoronavirusRNA, Messengerspike protein, SARS-CoV-2COVID-19 VaccinesLipid NanoparticlesAntibodies, MonoclonalLiposomes

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Department of Pathology and Experimental Pathology Graduate Program, University of Texas Medical Branch, Galveston, Texas, USA.
  • World Reference Center for Emerging Viruses and Arboviruses (WRCEVA), University of Texas Medical Branch, Galveston, Texas, USA.
  • CSIR - Indian Institute of Chemical Technology (IICT), Hyderabad, India.
  • R&D Division, Eureka Biotech Inc., Philadelphia, Pennsylvania, USA.
  • Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA.

ORCID-Profile: Haitao Hu

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Hazell, N. C., Reyna, R. A., Adam, A., Bonam, S. R., Bei, J., Kumar, N., Nguyen, T. N., Plante, J. A., Wu, T., Walker, D. H., Wang, T., Plante, K. S., & Hu, H. (2026). mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 in animal models. Journal of Virology. https://doi.org/10.1128/jvi.01897-25

Vancouver

Hazell NC, Reyna RA, Adam A, Bonam SR, Bei J, Kumar N, et al. mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 in animal models. Journal of Virology. 2026. doi:10.1128/jvi.01897-25

BibTeX
@article{Hazell2026,
  author = {Hazell, Nicholas C and Reyna, Rachel A and Adam, Awadalkareem and Bonam, Srinivasa Reddy and Bei, Jiani and Kumar, Naveen and Nguyen, Tina N and Plante, Jessica A and Wu, Tong and Walker, David H and Wang, Tian and Plante, Kenneth S and Hu, Haitao},
  title = {mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 in animal models},
  journal = {Journal of Virology},
  year = {2026},
  doi = {10.1128/jvi.01897-25}
}
Kostenlos starten →